WCM Investment Management LLC Cuts Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

WCM Investment Management LLC lessened its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 6.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 135,609 shares of the biopharmaceutical company’s stock after selling 9,740 shares during the period. WCM Investment Management LLC owned approximately 0.15% of Ultragenyx Pharmaceutical worth $5,732,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. CWM LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 9,552.5% during the third quarter. CWM LLC now owns 21,332 shares of the biopharmaceutical company’s stock valued at $1,185,000 after acquiring an additional 21,111 shares in the last quarter. nVerses Capital LLC grew its position in Ultragenyx Pharmaceutical by 237.5% during the 3rd quarter. nVerses Capital LLC now owns 2,700 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 1,900 shares during the last quarter. International Assets Investment Management LLC increased its stake in Ultragenyx Pharmaceutical by 29,580.0% during the 3rd quarter. International Assets Investment Management LLC now owns 10,388 shares of the biopharmaceutical company’s stock valued at $577,000 after purchasing an additional 10,353 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its holdings in Ultragenyx Pharmaceutical by 6.6% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 78,095 shares of the biopharmaceutical company’s stock worth $4,338,000 after buying an additional 4,806 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in shares of Ultragenyx Pharmaceutical by 2.3% in the third quarter. Assenagon Asset Management S.A. now owns 145,433 shares of the biopharmaceutical company’s stock worth $8,079,000 after buying an additional 3,259 shares in the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Trading Down 0.9 %

Shares of RARE stock opened at $45.35 on Monday. The company has a 50 day simple moving average of $44.00 and a two-hundred day simple moving average of $49.65. The stock has a market cap of $4.19 billion, a P/E ratio of -7.01 and a beta of 0.60. Ultragenyx Pharmaceutical Inc. has a 12 month low of $37.02 and a 12 month high of $60.37.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 11,727 shares of the business’s stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $42.23, for a total transaction of $495,231.21. Following the completion of the sale, the chief executive officer now owns 2,183,985 shares of the company’s stock, valued at approximately $92,229,686.55. The trade was a 0.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 5.80% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on RARE shares. HC Wainwright reissued a “buy” rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, December 24th. Wells Fargo & Company boosted their price target on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a research note on Friday, December 20th. Wedbush reaffirmed a “neutral” rating and set a $48.00 price objective (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. Piper Sandler lifted their price objective on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday, January 13th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 22nd. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $92.43.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.